You can choose the size of the video you would like to embed below. Next, copy the embed code that is available in the box below. Paste this code on to your website to display the video.
If you experience problems embedding videos, please contact us.
March 12, 2014 AT 11:40 AM
Pfizer Inccorporated said a federal court has invalidated a reissue patent that would have offered an additional 18 months of U.S. exclusivity — and monopoly sales — for its blockbuster painkiller Celebrex. The U.S. Patent and Trademark Office granted Pfizer a reissue patent a year ago, covering methods of treating osteoarthritis and other approved conditions with celecoxib, the active ingredient in Celebrex.